MTOR and rheumatoid arthritis: In summary, SB attenuates the PI3K/AKT/mTOR pathway and diminishes cytokine release by competitively binding to ICOS on PBMCs of RA patients, offering potential enhancements to UC‐MSCs therapeutic outcomes.